Moneycontrol
    Moneycontrol PRO

    Jump to

    • Hope to launch 12-15 new products in next one year: Strides Shasun

    • Book profits on rallies as Nifty is witnessing a ‘Bearish Butterfly’ on the charts

    • Strides Shasun deal could help create bigger franchise: Eris Lifesciences

    • Focus on B2C biz; aim to pare debt from proceeds of Eris Life deal: Strides Shasun

    • Will be vertically integrated formulation company: Strides Shasun

    • Remain bullish about performance overall in FY18: Strides Shasun

    • Sequent Scientific gets CCI approval for Scheme of Arrangement

    • Regulatory claims on Agila settled, says Strides Shasun

    • Data integrity issues hamper relations with regulators: Strides

    • Hope to complete merger formalities by October end: Shasun

    • Strides Arcolab to buy Aspen's generic biz in Australia

    • Special dividend of Rs 500/share to cost us $525mn: Strides

    • Ailing pharma sector needs uniform drug standards: Ranbaxy

      Given the fact that US gets 35 percent of its drugs from India, the regulator is only doing its job in looking closely at not just India's, but other countries‘ pharma units too, adds Ramesh Adige, former executive director, Ranbaxy.

    • Strides Arcolab arm in JV with Pfenex for biosimilar drugs

      Strides Arcolab‘s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market

    • Sale proceeds to help cut debt, repay FCCB: Strides Arcolab

      Strides Arcolab aims to use the funds received through the sale of its Southeast Asian and Australian units to repay foreign currency convertible bondholders and reduce the debt, says group chief executive and vice chairman Arun Kumar.

    • Strides Arcolab eyes 30-35% growth in current year

      In an interview with CNBC-TV18, Arun Kumar, Vice Chairman and MD, Strides Arcolab said Polymyxin is a small molecule, but currently it is in the shortage list of products. He further said the company will grow 30-35% in the current year.

    • Strides, Pfizer to deal post US FDA nod on Oncology unit

      Strides Arcolab received a nod by the US FDA for an Oncology unit in Bengaluru. Arun Kumar, group CEO and vice chairman of Strides Arcolab, in an exclusive interview with CNBC-TV18 shares that the company expects approvals on approximately USD 4-5 billon product filings in the next few weeks.

    • Strides Arcolab expects more approvals from US FDA soon

      In an interview with CNBC-TV18, Arun Kumar, Group CEO and Vice Chairman, Strides Arcolab spoke on the development and the way forward for the company.

    • Business to grow Rs 1000cr in FY11: Stride Arcolab

      Stride Arcolab announced it Q3 results for FY11. The company reported a consolidated net profit of Rs 122.4 crore for the year ended 2010 as against Rs 109.7 crore in previous year.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347